553502
Rac1 Inhibitor
Rac1 Inhibitor, CAS 1177865-17-6, is a cell-permeable, reversible inhibitor of Rac1 GDP/GTP exchange. Interferes with the interaction between Rac1 and Rac-specific GEFs Trio and Tiam1 (IC₅₀ ~50 µM).
Synonym(s):
Rac1 Inhibitor, NSC23766
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C24H38Cl3N7
CAS Number:
Molecular Weight:
530.96
UNSPSC Code:
12352200
Recommended Products
Quality Level
Assay
≥93% (HPLC)
form
lyophilized
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
desiccated (hygroscopic)
protect from light
solubility
water: 5 mg/mL
shipped in
ambient
storage temp.
2-8°C
InChI
1S/C24H35N7.3ClH/c1-6-31(7-2)12-8-9-16(3)27-24-28-18(5)14-23(30-24)29-19-10-11-22-20(15-19)21(25)13-17(4)26-22;;;/h10-11,13-16H,6-9,12H2,1-5H3,(H2,25,26)(H2,27,28,29,30);3*1H
InChI key
CPUHORIUXPQCHW-UHFFFAOYSA-N
General description
A cell-permeable pyrimidine compound that specifically and reversibly inhibits Rac1 GDP/GTP exchange activity by interfering with the interaction between Rac1 and Rac-specific GEFs (guanine nucleotide exchange factors) Trio and Tiam1 (IC50 ~50 µM). Shown to effectively inhibit Rac1-mediated cellular functions in NIH3T3 and PC-3 cells (effective dose ~50 to 100 μM). Exhibits no effect on Cdc42 or RhoA activation and does not affect Rac1 interaction with BcrGAP or PAK1. Reduces TRAP-induced and collagen stimulated platelet aggregation (IC50 = 50 mM and 64 mM, respectively).
Biochem/physiol Actions
Cell permeable: yes
Primary Target
Rac1
Rac1
Product does not compete with ATP.
Reversible: yes
Target IC50: ~50 µM against Rac1 GDP/GTP exchange activity; 50 mM and 64 mM against TRAP-induced and collagen stimulated platelet aggregation
Packaging
Packaged under inert gas
Warning
Toxicity: Carcinogenic / Teratogenic (D)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Dwivedi, S., et al. 2010. J. Translational Med.8, 128.
Desire, L., et al. 2005. J. Biol. Chem.280, 37516.
Gao, Y., et al. 2004. Proc. Natl. Acad. Sci. USA101, 7618.
Desire, L., et al. 2005. J. Biol. Chem.280, 37516.
Gao, Y., et al. 2004. Proc. Natl. Acad. Sci. USA101, 7618.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Shruthi Sriramkumar et al.
PloS one, 17(8), e0271584-e0271584 (2022-08-04)
Ovarian cancer (OC) is a lethal gynecological malignancy with a five-year survival rate of only 46%. Development of resistance to platinum-based chemotherapy is a common cause of high mortality rates among OC patients. Tumor and transcriptomic heterogeneity are drivers of
Kimia Ghaffari et al.
PLoS genetics, 17(3), e1009402-e1009402 (2021-03-20)
Impaired formation of the intrahepatic biliary network leads to cholestatic liver diseases, which are frequently associated with autoimmune disorders. Using a chemical mutagenesis strategy in zebrafish combined with computational network analysis, we screened for novel genes involved in intrahepatic biliary
Audrey Miller Williams et al.
eLife, 11 (2022-09-27)
For a group of cells to migrate together, each cell must couple the polarity of its migratory machinery with that of the other cells in the cohort. Although collective cell migrations are common in animal development, little is known about
Golnaz Morad et al.
International journal of molecular sciences, 21(11) (2020-06-03)
Breast cancer brain metastasis is a major clinical challenge and is associated with a dismal prognosis. Understanding the mechanisms underlying the early stages of brain metastasis can provide opportunities to develop efficient diagnostics and therapeutics for this significant clinical challenge.
Sonja Kühn et al.
Cell reports, 31(6), 107638-107638 (2020-05-14)
The enteroinvasive bacterium Shigella flexneri forces its uptake into non-phagocytic host cells through the translocation of T3SS effectors that subvert the actin cytoskeleton. Here, we report de novo actin polymerization after cellular entry around the bacterium-containing vacuole (BCV) leading to
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service